StockData
Picard Medical, Inc. logo

Picard Medical, Inc. (PMI) company profile

PMINYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3076% above fair value
$6.91−0.33 (-4.56%)

Close on Nov 17, 2026Market cap $16.16MP/E –Yield –

About Picard Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

Picard Medical, Inc., operating primarily through its subsidiary SynCardia Systems, LLC, is a medical technology company specializing in mechanical circulatory support. The company manufactures and commercializes total artificial heart systems designed to replace the function of failing ventricles and valves in patients with end-stage biventricular heart failure. Its core product offering includes the 50cc and 70cc artificial heart implants paired with external pneumatic power systems: the mobile Companion 2 Driver for clinical inpatient stabilization and the lightweight Freedom Driver for outpatient home care. These devices serve primarily as a bridge to heart transplantation for hospitals, cardiac transplant centers, and surgeons treating critically ill patients.

The business operates internationally, with more than 2,100 artificial hearts implanted across 27 countries. Commercial availability centers on the United States and Canada, supported by entities and activities in Australia, China, and Germany. SynCardia maintains its operational headquarters in Tucson, Arizona.

Summary of the business section of Picard Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Picard Medical, Inc.
Founded
2021
Headquarters
Tucson, AZ
Address
1992 E. Silverlake Rd. 85713
Phone
(520) 308-0796
Employees
75, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
PMI
Exchange
NYSE
IPO date
Sep 2, 2025
Shares outstanding
2M, Aug 18, 2026
Public float
$130.82M, Sep 2, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-50 reverse, Aug 3, 2026
SEC CIK
2030617
CUSIP
71953R108
ISIN
US71953R1086
FIGI
BBG000TR9Y22
Share class FIGI
BBG001T9HQK8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Patrick Nj SchnegelsbergChief Executive Officer, Director–
Matt SchusterChief Operating Officer–
Bernard SkaggsChief Financial Officer–
George Tiancheng YeDirector–
Richard FangDirector–
Van SamDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryTotalvs. prior year
Patrick NJ Schnegelsberg
Former Chief Executive Officer
$400.00K$400.00K-76%
Bernard Skaggs
Former Chief Financial Officer
$200.00K$200.00K-58%
Matt Schuster
Chief Operating Officer
$220.00K$220.00K-58%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 2, 2025
Offer price
$4.00
Securities offered
4,250,000
Gross proceeds
$17.00M
Exchange
NYSE
First trading day
Sep 2, 2025
First-day close
$5.14+28.5%
Lock-up ends (est.)
Mar 1, 2026

“The initial public offering price is $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?